ClinicalTrials.gg
CompletedNCT07804979Updated Sep 4, 2026

Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder

An interventional study of Minocycline and Celecoxib in Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD), sponsored by Lahore General Hospital. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Lahore General Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled May 2022, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Depressive Disorder, Major with a site in Pakistan — 7 open to participants now, 7 under way, 1 of them phase 3. Depressive Disorder, Major · Pakistan.

Enrollment
13th of 17
78 · median 80
Started
2022
with 2 others
No phase
13 of 18
6 open now
Registered
18th of 18
by date

Among the 18 studies in Depressive Disorder, Major with a site in Pakistan, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2022, is one of 13 with no phase, and was the 18th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 18 studies in Depressive Disorder, Major with a site in Pakistan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Depressive Disorder, Major with a site in Pakistan, or all of them as a file.
02

Study summary

This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder. Treatment-resistant depression was defined as depression that had not adequately improved despite appropriate previous antidepressant treatment. A total of 78 patients aged 18-65 years were enrolled from the Psychiatry Department of Lahore General Hospital, Lahore, and were randomly assigned to two treatment groups. One group received minocycline 100 mg twice daily with fluoxetine 20-40 mg, while the other group received celecoxib 200 mg twice daily with fluoxetine 20-40 mg. Treatment was continued for 12 weeks.

Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HAM-D) at baseline and during follow-up. The main outcome was the change in HAM-D score from baseline to the end of treatment. Treatment response was defined as a reduction of at least 50% in the HAM-D score, while remission was defined as a final HAM-D score of 7 or lower. The study was designed to test whether adding minocycline or celecoxib to fluoxetine would reduce depressive symptoms in treatment-resistant major depressive disorder and whether the degree of improvement differed between the two adjunctive treatments.

03

Conditions studied

  • Major Depressive Disorder (MDD)
  • Treatment-resistant Depression (TRD)

Keywords

  • Major Depressive Disorder
  • Treatment-Resistant Depression
  • Minocycline
  • Celecoxib
  • Fluoxetine
  • Adjunctive Drug Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-65 years.
  • Patients of either gender.
  • Patients with a current diagnosis of Major Depressive Disorder.
  • Voluntary outpatients who were competent to provide .
  • Patients with a baseline Hamilton Depression Rating Scale (HAM-D) score >14.
  • Patients fulfilling the study definition of Treatment-Resistant Depression (TRD).

Exclusion criteria

Exclusion Criteria:

  • Patients with psychotic depression.
  • Patients already taking either of the trial drugs, based on the medical record.
  • Patients with substance use disorder or dependence within the previous 3 months.
  • Pregnant women, women planning to conceive within 3 months, or breastfeeding women.
  • Patients with another primary psychiatric disorder already receiving treatment.
  • Patients with a history of intolerance or allergy to minocycline or celecoxib.
  • Patients with active renal, hepatic, cardiac, or serious dermatological illness.
  • Patients receiving concomitant penicillin therapy or anticoagulants.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Group Minocycline

    Participants received minocycline 100 mg orally twice daily as adjunctive treatment, along with fluoxetine 20-40 mg orally per day, for 12 weeks.

    Drug: Minocycline

  • Active comparator
    Group Celecoxib

    Participants received celecoxib 200 mg orally twice daily as adjunctive treatment, along with fluoxetine 20-40 mg orally per day, for 12 weeks.

    Drug: Celecoxib

Interventions

  • Minocycline 100 mg orally twice daily was administered in addition to fluoxetine 20-40 mg/day for 12 weeks.

  • Celecoxib 200 mg orally twice daily was administered in addition to fluoxetine 20-40 mg/day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Rating Scale (HAM-D) Score

    The primary outcome was the mean change in Hamilton Depression Rating Scale (HAM-D) score from baseline to the end of treatment. HAM-D was used to assess the severity of depressive symptoms. The change in HAM-D score was calculated by comparing the baseline score with the score obtained after 12 weeks of adjunctive treatment. A greater reduction in HAM-D score indicated greater improvement in depressive symptoms.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Treatment Response Based on HAM-D Score

    Treatment response was defined as a reduction of 50% or more in the HAM-D score from baseline during the 12-week treatment period. The proportion of participants achieving treatment response was assessed in each treatment group.

    Time frame: Baseline to 12 weeks

07

Study locations

1 site
  • Lahore General Hospital, Lahore
    Lahore, Punjab Province 54000, Pakistan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2023, 13 months.

Of 651 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's 13 months is below that.

Counting every sponsor, half of 691 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 4, 2026
StartActual
May 12, 2022
Primary completionActual
Jun 17, 2023
CompletionActual
Sep 15, 2023
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07804979
Lead sponsor
Lahore General Hospital
Responsible party
Muhammad Irfan Jamil (Principal Investigator, Lahore General Hospital) — Principal investigator
First posted
Sep 4, 2026
Start date
May 12, 2022
Primary completion
Jun 17, 2023
Completion
Sep 15, 2023
Last update
Sep 4, 2026

Study contacts

Farhana Ashraf
principal investigator · Lahore General Hospital, Lahore

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minocycline

Start the discussion